Coagulation factor VIIa Recombinant Human
- Generic Name
- Coagulation factor VIIa Recombinant Human
- Brand Names
- Niastase RT, Novoseven, Sevenfact, NovoSeven
- Drug Type
- Biotech
- CAS Number
- 102786-61-8
- Unique Ingredient Identifier
- AC71R787OV
Overview
Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Background
Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
Indication
For treatment of hemorrhagic complications in hemophilia A and B.
Associated Conditions
- Bleeding
- Bleeding caused by Hemophilia A
- Bleeding caused by Hemophilia B
- Severe Bleeding
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.